The AIM-HI Beacon Award for Women Leaders in Oncology recognizes outstanding women leaders in all sectors of the health and life sciences industry who have made a significant impact on advancing cancer treatment, detection, and diagnosis for patients worldwide through the development and commercialization of novel technologies, advocacy, and/or implementation of public policy.
The AIM-HI Accelerator Fund (AIM-HI) is pleased to announce the recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology as Monica M. Bertagnolli, M.D., Director of the National Cancer Institute (NCI).
Dr. Bertagnolli was honored at a luncheon award ceremony at the National Press Club in Washington, D.C., on October 21, 2023. The award ceremony was part of the 2023 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, which brought together world-renowned leaders in cancer research and drug development as well as business leaders, government officials, and donors/investors. Click here to Read the Event Recap.
We encourage you to visit our Oncology Metaverse to view the recorded videos from the event and hear inspiring speeches and discussions from world-class researchers, clinicians, entrepreneurs, industry leaders, investors, advocates, and cancer patients and survivors.
- Sujuan Ba, Ph.D., Co-Chair, CEO & Co-Founder, AIM-HI Accelerator Fund; President & CEO, National Foundation for Cancer Research
- Webster Cavenee, Ph.D., Co-Chair, Distinguished Professor Emeritus, University of California San Diego
- Deborah Dunsire, M.D., President & CEO, Lundbeck
- Karen Knudsen, MBA, Ph.D., CEO, American Cancer Society
- Andrew Plump, M.D., Ph.D., President, Research & Development, Takeda Pharmaceutical
- Daniel Von Hoff, M.D., F.A.C.P., Distinguished Professor, Translational Genomics Research Institute (TGen)
Together, we can make the next generation of cancer treatments a reality.